{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:48:28Z","timestamp":1787010508760,"version":"build-2736575974"},"reference-count":61,"publisher":"The Royal Society","issue":"1671","license":[{"start":{"date-parts":[[2015,6,19]],"date-time":"2015-06-19T00:00:00Z","timestamp":1434672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/royalsociety.org\/journals\/ethics-policies\/data-sharing-mining\/"}],"content-domain":{"domain":["royalsocietypublishing.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2015,6,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Thanks to the Global Alliance for Vaccines and Immunization (GAVI), the Vaccine Fund and the Bill &amp; Melinda Gates Foundation, the global health community has made enormous progress in providing already existing vaccines to developing countries. However, there still exists a gap to develop vaccines for which there is no market in the Western world, owing to low economic incentives for the private sector to justify the investments necessary for vaccine development. In many cases, industry has the technologies, but lacks the impetus to direct resources to develop these vaccine products. The present emergency with the Ebola vaccine provides us an excellent example where a vaccine was feasible several years ago, but the global health community waited for a humanitarian disaster to direct efforts and resources to develop this vaccine. In the beginning of 2015, the first large-scale trials of two experimental vaccines against Ebola virus disease have begun in West Africa. During the past few years, several institutions have dedicated efforts to the development of vaccines against diseases present only in low-income countries. These include the International Vaccine Institute, the Novartis Vaccines Institute for Global Health, the Hilleman Institute, the Sabin Vaccine Institute and the Infectious Disease Research Institute. Nevertheless, solving this problem requires a more significant global effort than that currently invested. These efforts include a clear policy, global coordination of funds dedicated to the development of neglected disease and an agreement on regulatory strategies and incentives for the private sector.<\/jats:p>","DOI":"10.1098\/rstb.2014.0150","type":"journal-article","created":{"date-parts":[[2015,5,11]],"date-time":"2015-05-11T20:41:03Z","timestamp":1431376863000},"update-policy":"https:\/\/doi.org\/10.1098\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Delivering vaccines to the people who need them most"],"prefix":"10.1098","volume":"370","author":[{"given":"Mich\u00e8le Anne","family":"Barocchi","sequence":"first","affiliation":[{"name":"Novartis Vaccines and Diagnostics, Siena ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rino","family":"Rappuoli","sequence":"additional","affiliation":[{"name":"Novartis Vaccines and Diagnostics, Siena ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"175","reference":[{"key":"2026010103383014400_RSTB20140150C1","volume-title":"The future of public health","author":"Institute of Medicine","year":"1988"},{"key":"2026010103383014400_RSTB20140150C2","doi-asserted-by":"crossref","first-page":"12 288","DOI":"10.1073\/pnas.1402981111","article-title":"Vaccines, new opportunities for a new society","volume":"111","author":"Rappuoli,","year":"2014","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2026010103383014400_RSTB20140150C3","unstructured":"World Health Organization. 2013 Global Vaccine Action Plan (GVAP). See http:\/\/www.who.int\/immunization\/global_vaccine_action_plan\/en\/. From empiricism to rational design: a personal perspective of the evolution of vaccine development."},{"key":"2026010103383014400_RSTB20140150C4","unstructured":"World Health Organization. 1999 Initiative for Vaccine Research. See http:\/\/www.who.int\/immunization\/research\/en\/."},{"key":"2026010103383014400_RSTB20140150C5","first-page":"1","article-title":"Vaccines and vaccination in historical perspective","volume-title":"New generation vaccines","author":"Levine,","year":"2004","edition":"3rd edn"},{"key":"2026010103383014400_RSTB20140150C6","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1038\/nbt1207-1361","article-title":"Bridging the knowledge gaps in vaccine design","volume":"25","author":"Rappuoli,","year":"2007","journal-title":"Nat. Biotechnol."},{"key":"2026010103383014400_RSTB20140150C7","first-page":"389","article-title":"A centennial celebration: Pasteur and the modern era of immunization","volume":"34","author":"Centers for Disease Control (CDC)","year":"1985","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"issue":"(4 Suppl)","key":"2026010103383014400_RSTB20140150C8","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1038\/nm1209","article-title":"Vaccines: past, present and future","volume":"11","author":"Plotkin,","year":"2005","journal-title":"Nat. Med."},{"key":"2026010103383014400_RSTB20140150C9","doi-asserted-by":"crossref","DOI":"10.1002\/0471142905.hg1302s37","article-title":"DNA vaccination","author":"Ulmer,","year":"2003","journal-title":"Curr. Protoc. Hum. Genet"},{"key":"2026010103383014400_RSTB20140150C10","doi-asserted-by":"crossref","first-page":"4434","DOI":"10.1016\/j.vaccine.2008.05.073","article-title":"SAGE subgroup. Optimising the use of conjugate vaccines to prevent disease caused by Haemophilus influenzae type b, Neisseria meningitidis and Streptococcus pneumoniae","volume":"26","author":"Trotter,","year":"2008","journal-title":"Vaccine"},{"key":"2026010103383014400_RSTB20140150C11","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1038\/nm1129","article-title":"From Pasteur to genomics: progress and challenges in infectious diseases","volume":"10","author":"Rappuoli,","year":"2004","journal-title":"Nat. Med."},{"key":"2026010103383014400_RSTB20140150C12","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1016\/j.febslet.2006.04.084","article-title":"Post-genomic vaccine development","volume":"580","author":"Serruto,","year":"2006","journal-title":"FEBS Lett."},{"key":"2026010103383014400_RSTB20140150C13","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1126\/science.1092329","article-title":"Reverse vaccinology and genomics","volume":"302","author":"Rappuoli,","year":"2003","journal-title":"Science"},{"key":"2026010103383014400_RSTB20140150C14","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1126\/science.287.5459.1816","article-title":"Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing","volume":"287","author":"Pizza,","year":"2000","journal-title":"Science"},{"key":"2026010103383014400_RSTB20140150C15","doi-asserted-by":"crossref","first-page":"10 834","DOI":"10.1073\/pnas.0603940103","article-title":"A universal vaccine for serogroup B meningococcus","volume":"103","author":"Giuliani,","year":"2006","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2026010103383014400_RSTB20140150C16","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1179\/2047773214Y.0000000162","article-title":"Bexsero chronicle","volume":"108","author":"Vernikos,","year":"2014","journal-title":"Pathog. Glob. Health"},{"key":"2026010103383014400_RSTB20140150C17","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.tibtech.2008.08.002","article-title":"Structure-based antigen design: a strategy for next generation vaccines","volume":"26","author":"Dormitzer,","year":"2008","journal-title":"Trends Biotechnol."},{"key":"2026010103383014400_RSTB20140150C18","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nri3694","article-title":"From empiricism to rational design: a personal perspective of the evolution of vaccine development","volume":"14","author":"De Gregorio,","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"2026010103383014400_RSTB20140150C19","doi-asserted-by":"crossref","first-page":"91ra62","DOI":"10.1126\/scitranslmed.3002234","article-title":"Rational design of a meningococcal antigen inducing broad protective immunity","volume":"3","author":"Scarselli,","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"2026010103383014400_RSTB20140150C20","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1126\/science.1243283","article-title":"Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus","volume":"342","author":"McLellan,","year":"2013","journal-title":"Science"},{"key":"2026010103383014400_RSTB20140150C21","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1010331","article-title":"Oil-in-water emulsion adjuvant with influenza vaccine in young children","volume":"365","author":"Vesikari,","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"2026010103383014400_RSTB20140150C22","doi-asserted-by":"crossref","first-page":"234ra55","DOI":"10.1126\/scitranslmed.3008761","article-title":"A cell culture-derived MF59-adjuvanted pandemic A\/H7N9 vaccine is immunogenic in adults","volume":"6","author":"Bart,","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"2026010103383014400_RSTB20140150C23","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1586\/erv.11.192","article-title":"Development and evaluation of AS03, an adjuvant system containing \u03b1-tocopherol and squalene in an oil-in-water emulsion","volume":"11","author":"Gar\u00e7on,","year":"2012","journal-title":"Expert Rev. Vaccines"},{"key":"2026010103383014400_RSTB20140150C24","article-title":"Chimpanzee adenovirus vector Ebola vaccine\u2014preliminary report","author":"Ledgerwood,","journal-title":"N. Engl. J. Med"},{"key":"2026010103383014400_RSTB20140150C25","doi-asserted-by":"crossref","first-page":"185ra68","DOI":"10.1126\/scitranslmed.3006368","article-title":"Synthetic generation of influenza vaccine viruses for rapid responses to pandemics","volume":"5","author":"Dormitzer,","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"2026010103383014400_RSTB20140150C26","doi-asserted-by":"crossref","first-page":"14 604","DOI":"10.1073\/pnas.1209367109","article-title":"Nonviral delivery of self-amplifying RNA vaccines","volume":"109","author":"Geall,","year":"2012","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2026010103383014400_RSTB20140150C27","doi-asserted-by":"crossref","first-page":"e52","DOI":"10.1038\/emi.2013.54","article-title":"Rapidly produced SAM\u00ae vaccine against H7N9 influenza is immunogenic in mice","volume":"2","author":"Hekele,","year":"2013","journal-title":"Emerg. Microbes Infect."},{"key":"2026010103383014400_RSTB20140150C28","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1056\/NEJMms1215400","article-title":"Contagious diseases in the United States from 1888 to the present","volume":"369","author":"van Panhuis,","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"2026010103383014400_RSTB20140150C29","first-page":"619","article-title":"Ten great public health achievements\u2014United States, 2001\u20132010","volume":"60","author":"Centers for Disease Control and Prevention (CDC)","year":"2011","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"2026010103383014400_RSTB20140150C30","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1056\/NEJMoa1102287","article-title":"First results of phase 3 trial of RTS,S\/AS01 malaria vaccine in African children","volume":"365","author":"RTS,S Clinical Trials Partnership","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"2026010103383014400_RSTB20140150C31","doi-asserted-by":"crossref","first-page":"12 307","DOI":"10.1073\/pnas.1400473111","article-title":"Vaccines against poverty","volume":"111","author":"MacLennan,","year":"2014","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2026010103383014400_RSTB20140150C32","first-page":"858","article-title":"Global routine vaccination coverage--2012","volume":"62","author":"Centers for Disease Control and Prevention (CDC)","year":"2013","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"key":"2026010103383014400_RSTB20140150C33","unstructured":"GAVI Alliance. 2014Saving children's lives and protecting people's health by increasing access to immunisation in poor countries. See http:\/\/www.gavialliance.org\/."},{"key":"2026010103383014400_RSTB20140150C34","unstructured":"BIOventures for Global Health 2012 Developing new drugs and vaccines for neglected diseases of the poor. 2012The Product Developer Landscape. See http:\/\/www.bvgh.org\/Portals\/0\/Reports\/2012_03_developing_new_drugs_and_vaccines_for_neglected_diseases.pdf."},{"key":"2026010103383014400_RSTB20140150C35","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3855\/T2.2.154","article-title":"The Novartis Vaccines Institute for Global Health: a new initiative for developing vaccines for neglected diseases in developing countries","volume":"2","author":"Saul,","year":"2009","journal-title":"J. Infect. Dev."},{"key":"2026010103383014400_RSTB20140150C36","doi-asserted-by":"crossref","first-page":"e570","DOI":"10.1016\/S2214-109X(14)70301-8","article-title":"Burden of typhoid fever in low-income and middle-income countries: a systematic, literature-based update with risk-factor adjustment","volume":"2","author":"Mogasale,","year":"2014","journal-title":"Lancet Glob. Health."},{"key":"2026010103383014400_RSTB20140150C37","doi-asserted-by":"crossref","first-page":"010401","DOI":"10.7189\/jogh.01.010401","article-title":"Typhoid fever and paratyphoid fever: systematic review to estimate global morbidity and mortality for 2010","volume":"2","author":"Buckle,","year":"2012","journal-title":"J. Glob. Health"},{"key":"2026010103383014400_RSTB20140150C38","doi-asserted-by":"crossref","first-page":"404","DOI":"10.3855\/jidc.1048","article-title":"Conjugate vaccines for enteric fever: proceedings of a meeting organized in New Delhi, India in 2009","volume":"4","author":"Podda,","year":"2010","journal-title":"J. Infect. Dev."},{"key":"2026010103383014400_RSTB20140150C39","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.vaccine.2010.11.022","article-title":"Vi-CRM 197 as a new conjugate vaccine against Salmonella Typhi","volume":"29","author":"Micoli,","year":"2011","journal-title":"Vaccine"},{"key":"2026010103383014400_RSTB20140150C40","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S1473-3099(13)70241-X","article-title":"Immunogenicity and safety of the Vi-CRM197 conjugate vaccine against typhoid fever in adults, children, and infants in south and southeast Asia: results from two randomised, observer-blind, age de-escalation, phase 2 trials","volume":"14","author":"Bhutta,","year":"2014","journal-title":"Lancet. Infect. Dis."},{"key":"2026010103383014400_RSTB20140150C41","unstructured":"World Health Organization. 2015Ebola vaccines, therapy, vaccines and diagnostics. See http:\/\/www.who.int\/medicines\/emp_ebola_q_as\/en\/."},{"key":"2026010103383014400_RSTB20140150C42","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/519263a","article-title":"Share the risks of Ebola vaccine development","volume":"519","author":"Berkley,","year":"2015","journal-title":"Nature"},{"key":"2026010103383014400_RSTB20140150C43","unstructured":"World Health Organization. 2014Global strategy for dengue prevention control: 2012\u20132020. See http:\/\/www.who.int\/denguecontrol\/9789241504034\/en\/."},{"key":"2026010103383014400_RSTB20140150C44","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1411037","article-title":"Efficacy of a tetravalent dengue vaccine in children in Latin America","volume":"372","author":"Villar,","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"2026010103383014400_RSTB20140150C45","doi-asserted-by":"crossref","first-page":"6046","DOI":"10.1016\/j.vaccine.2013.08.008","article-title":"The role of health economic analyses in vaccine decision making","volume":"31","author":"Black,","year":"2013","journal-title":"Vaccine"},{"key":"2026010103383014400_RSTB20140150C46","doi-asserted-by":"crossref","first-page":"204ed16","DOI":"10.1126\/scitranslmed.3007588","article-title":"Vaccine economics: what price has human life?","volume":"5","author":"Mekalanos,","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"2026010103383014400_RSTB20140150C47","unstructured":"Institute of Medicine of the National Academies. 2012Ranking vaccines: a prioritization framework\u2014phase I: demonstration of concept and a software blueprint. See www.nap.edu\/smartvaccines."},{"key":"2026010103383014400_RSTB20140150C48","unstructured":"Institute of Medicine of the National Academies. 2013Ranking vaccines: a prioritization software tool\u2014phase II: prototype of a decision-support system. See www.nap.edu\/smartvaccines."},{"key":"2026010103383014400_RSTB20140150C49","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1073\/pnas.1400945111","article-title":"A priority-setting aid for new vaccine candidates","volume":"111","author":"Phelps,","year":"2014","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2026010103383014400_RSTB20140150C50","doi-asserted-by":"crossref","first-page":"12 313","DOI":"10.1073\/pnas.1400475111","article-title":"Valuing vaccination","volume":"111","author":"B\u00e4rnighausen,","year":"2014","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2026010103383014400_RSTB20140150C51","unstructured":"Institute for Health Metrics and Evaluation. 2010Global Burden of Diseases, Injuries, and Risk Factors study 2010. See www.healthmetricsandevaluation.org\/gbd\/research\/project\/globalburdendiseases-injuries-and-risk-factors-study-2010."},{"key":"2026010103383014400_RSTB20140150C52","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","article-title":"Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Lozano,","year":"2012","journal-title":"Lancet"},{"key":"2026010103383014400_RSTB20140150C53","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/S0140-6736(12)61689-4","article-title":"Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990\u20132010: a systematic analysis for the Global Burden of Disease Study 2010","volume":"380","author":"Murray,","year":"2012","journal-title":"Lancet"},{"key":"2026010103383014400_RSTB20140150C54","unstructured":"PATH. 2014Malaria Vaccine Initiative. See http:\/\/www.malariavaccine.org\/."},{"key":"2026010103383014400_RSTB20140150C55","unstructured":"Global HIV Vaccine Enterprise. 2014Global HIV Vaccine Enterprise. See http:\/\/www.vaccineenterprise.org\/."},{"key":"2026010103383014400_RSTB20140150C56","unstructured":"AERAS. 2014AERAS advancing tuberculosis vaccines for the world. See http:\/\/www.aeras.org."},{"key":"2026010103383014400_RSTB20140150C57","doi-asserted-by":"crossref","first-page":"e1001685","DOI":"10.1371\/journal.pmed.1001685","article-title":"Efficacy and safety of the RTS,S\/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites","volume":"11","author":"RTS,S Clinical Trials Partnership","year":"2014","journal-title":"PLoS Med."},{"key":"2026010103383014400_RSTB20140150C58","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1016\/S0140-6736(10)60736-2","article-title":"The Health Impact Fund","volume":"375","author":"Banerjee,","year":"2010","journal-title":"Lancet"},{"key":"2026010103383014400_RSTB20140150C59","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/S0140-6736(09)61296-4","article-title":"The Health Impact Fund: incentives for improving access to medicines","volume":"375","author":"Banerjee,","year":"2010","journal-title":"Lancet"},{"key":"2026010103383014400_RSTB20140150C60","unstructured":"Health Impact Fund. 2015See http:\/\/healthimpactfund.org\/."},{"key":"2026010103383014400_RSTB20140150C61","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1016\/S0140-6736(13)62105-4","article-title":"Global Health 2035: a world converging within a generation","volume":"382","author":"Jamison,","year":"2013","journal-title":"Lancet"}],"container-title":["Philosophical Transactions of the Royal Society B: Biological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/royalsocietypublishing.org\/doi\/pdf\/10.1098\/rstb.2014.0150","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/royalsocietypublishing.org\/doi\/full-xml\/10.1098\/rstb.2014.0150","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/royalsocietypublishing.org\/rstb\/article-pdf\/doi\/10.1098\/rstb.2014.0150\/108408\/rstb.2014.0150.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/royalsocietypublishing.org\/rstb\/article-pdf\/doi\/10.1098\/rstb.2014.0150\/108408\/rstb.2014.0150.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T08:38:43Z","timestamp":1767256723000},"score":1,"resource":{"primary":{"URL":"https:\/\/royalsocietypublishing.org\/rstb\/article\/370\/1671\/20140150\/22539\/Delivering-vaccines-to-the-people-who-need-them"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,19]]},"references-count":61,"journal-issue":{"issue":"1671","published-print":{"date-parts":[[2015,6,19]]}},"URL":"https:\/\/doi.org\/10.1098\/rstb.2014.0150","relation":{},"ISSN":["0962-8436","1471-2970"],"issn-type":[{"value":"0962-8436","type":"print"},{"value":"1471-2970","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,19]]},"assertion":[{"value":"2015-03-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-06-19","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"20140150"}}